接受 tisagenlecleucel 治疗的儿科患者持续性重度中性粒细胞减少的特征与预测

Hematotoxicity is the most frequent severe toxicity after chimeric antigen receptor T-cell (CAR-T) therapy.

However, limited data exist on risk factors and outcomes for hematotoxicity for children and young adults (CAYAs) with B-acute lymphoblastic leukemia treated with tisagenlecleucel.

We conducted a multi-institutional study involving 326 CAYAs, with 144 evaluable in an initial training cohort and 141 evaluable in a validation cohort, through the Pediatric Real-World CAR Consortium to characterize the incidence and outcomes of prolonged severe neutropenia (PSN) and to develop a predictive risk score for PSN, tailored for use in this population. The incidence of PSN, defined as an absolute neutrophil count of <0. 5 x 103 cells per L for 30 days, was 15. 3% in the initial training cohort and 21% in the validation cohort. Development of PSN was associated with inferior overall survival (P < . 001), relapse-free survival (P = . 01), higher nonrelapse mortality (P = .

003), and a greater risk of infections within 30 days (P = . 03). Multivariable penalized regression analysis identified key risk factors for PSN, which included preinfusion C-reactive protein and bone marrow disease burden, and postinfusion peak ferritin and occurrence of severe cytokine release syndrome, which were used to create the CytoRisk score.

In the validation cohort, the CytoRisk score discriminated between patients with and without PSN (area under the curve, 0. 90; specificity, 93%; sensitivity, 71%; positive predictive value, 74%; and negative predictive value, 92%). The CytoRisk score may be used to a priori identify patients at highest risk of PSN and overall worse outcomes.